Non-invasive system and method for predicting physiological substrate ablation targets - Patents.com
A method and system analyze body surface ECG components using regular and extra-stimuli pacing signals to detect DeEP, addressing the lack of non-invasive prediction tools for ablation targets, enhancing the safety and efficacy of invasive procedures.
Patent Information
- Application Number
- JP2024534733
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-09
- Filing Date
- 2022-12-11
- Publication Date
- 2024-12-05
AI Technical Summary
Current methods lack non-invasive tools to predict the presence of decreased evoked potentials (DeEP) on a 12-lead ECG before or during invasive electrophysiological procedures, which are crucial for identifying potential ablation targets in patients with ventricular tachycardia.
A method and system that utilize a series of regular and extra-stimuli pacing signals to analyze body surface ECG components, comparing the envelopes of these signals to detect DeEP, which are indicative of abnormal electrical propagation in the heart, allowing for non-invasive prediction of ablation targets.
Enables the non-invasive detection of DeEP, improving the safety and efficacy of diagnostic catheterization procedures by predicting substrate ablation targets before invasive procedures, thereby enhancing patient screening and treatment planning.
Smart Images

Figure 2024545192000001_ABST
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of U.S. Provisional Patent Application No. 63 / 288,633, filed December 12, 2021, which is incorporated by reference as if fully set forth herein.
[0002] FIELD OF THEINVENTION The present invention relates generally to electrophysiological (EP) signals, and more particularly to a method for non-invasively detecting abnormal electrical propagation within the heart, which may be utilized to screen patients for invasive EP procedures. [Background technology]
[0003] Depleted evoked potentials (DeEPs) are used to identify VT substrate ablation targets without the need to induce ventricular tachycardia (VT). These potentials are identified by invasive intracardiac mapping protocols. It would be of practical benefit to predict which patients would be ideal for such physiological mapping protocols prior to an invasive procedure. There are no non-invasive tools to predict the higher probability of DeEPs in a 12-lead ECG (electrocardiogram) before or during the procedure, which could be useful for electrophysiologists performing the ablation. Summary of the Invention [Means for solving the problem]
[0004] A method is disclosed for assessment of electrical propagation within a heart, the method including receiving a pacing signal for application to a patient's heart, the pacing signal including (i) a series of regular pacing stimuli (S1 paces) at intervals slightly less than a sinus rhythm interval, and (ii) one or more premature pacing stimuli (S2, S3, etc., paces) at intervals less than the regular pacing intervals, evaluating an envelope of a surface ECG component after the regular pacing stimuli, evaluating an envelope of the surface ECG component after the extrastimuli, comparing the evaluated component after the extrastimuli to the evaluated component after the regular pacing stimuli, and outputting the comparison as an indication of the presence of a decrement-evoked potential (DeEP) within the patient's heart.
[0005] A system for non-invasively detecting abnormal electrical propagation in the heart is disclosed. The system includes an interface configured to receive a pacing signal applied to a patient's heart using an existing implantable device, such as an Automatic Intracardiac Cardioverter-Defibrillator (AICD) or a pacemaker, the pacing signal including (i) a series of regular pacing stimuli (S1 pace) at intervals slightly shorter than the sinus rhythm interval, (ii) one or more premature pacing stimuli (S2, S3, etc. paces) at intervals shorter than the regular pacing interval, and a cardiac signal sensed by a surface ECG in response to the pacing signal. The system includes a processor configured to evaluate an envelope of a surface ECG component after the regular pacing stimuli, evaluate an envelope of a surface ECG component after the premature stimuli, and compare the evaluated component after the premature stimuli with the evaluated component after the regular pacing stimuli. The interface is further configured to output the comparison as an indication of the presence of DeEP in the patient's heart.
[0006] The system and method includes at least one system component that includes measurements of surface ECG component characteristics, such as QRS envelope duration, voltage, area under the curve, slope, frequency analysis, and envelope height. The system and method includes measurements of QRS envelope duration of 0-10 ms that indicate no ablation target, QRS envelope duration of 10-50 ms that indicate positive DeEP, and QRS envelope duration of greater than 50 ms that indicate the presence of significant DeEP. [Brief description of the drawings]
[0007] A more complete understanding of the present disclosure will be obtained from the following detailed description of the embodiments of the present disclosure when read in conjunction with the drawings. [Figure 1] 1 is a schematic diagram of a multi-channel electrocardiogram (ECG) signal measurement system, according to one embodiment. [Diagram 2] 1 illustrates an example of multiple surface ECG signals indicative of a patient having decreased evoked potentials (DeEPs) within the heart, according to an exemplary embodiment. [Diagram 3] 3A, 3B, and 3C, provide examples of multiple surface ECG signals having QRS widening associated with cases indicative of the presence of DeEP, according to an exemplary embodiment. [Figure 4] 1 illustrates a method for automatically assessing a surface ECG for the presence of DeEP, according to one embodiment. [Diagram 5] 1 shows an example of multiple surface ECG signals of a patient when pacing is performed from the coronary sinus. [Figure 6] 6 shows an example of multiple surface ECG signals for the patient of FIG. 5 when pacing is performed from the right ventricular apex. [Figure 7] We demonstrate how pacing from different locations can be used to automatically assess surface ECGs for the presence of DeEPs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] Cardiac tachycardia, such as ventricular tachycardia (VT) or atrial tachycardia, is a heart rhythm disorder (arrhythmia) caused by abnormal electrical signals in the heart chambers. For example, VT may be caused by abnormal electrical signals in the lower chambers (ventricles) of the heart. VT may be caused by local electrophysiological (EP) conduction defects in ventricular tissue, such as scar tissue. To find and treat such arrhythmia sites, for example by ablation, the ventricles may be paced and EP mapped using a surface ECG and / or an intracardiac catheter to identify abnormal tissue locations (e.g., locations that exhibit DeEP) that may be causing the VT.
[0009] In particular, EP mapping may be performed to support therapeutic approaches targeting arrhythmogenic channels and sites, which has proven useful for ablating scar tissue across the scar. The motivation behind ablative therapy is to target poorly connected ventricular tissue fibers that survive within the resulting scar. These bundles are believed to generate EP pathways that exhibit slow conduction (scar isthmus) that are believed to be the cause of VT.
[0010] In one scenario, a tachycardia may be initiated during an EP study to perform EP mapping of the pathways and circuits leading to the tachycardia. However, VT is often uninducible or hemodynamically unstable, and therefore substrate mapping is often required. In substrate mapping, the properties of tissue in sinus rhythm or ventricular pacing are related to the arrhythmogenicity of the tissue.
[0011] DeEP mapping is a substrate mapping technique. The basis of the method is that ventricular tissue that shows reduced conduction with reduced premature stimulation appears to be more specific for abnormal VT circuits. DeEP information is typically presented as a layer of DeEP data superimposed on a ventricular EP map.
[0012] In the disclosed technique, the ventricles are paced with short sequences of regular pulses that are slightly faster than sinus rhythm. The short sequences are terminated with one or more pulses (typically up to three) with shorter inter-beat intervals. Common notation defines this as pacing with a train of S1 paces (usually, but not always, having a 600 millisecond cycle length) followed by one or more reduced extrastimuli (S2, S3, etc.) delivered immediately (e.g., 20 milliseconds after) a period during which new action potentials normally cannot be initiated (commonly referred to as the refractory period), thereby stimulating the arrhythmogenic response being sought in the abnormal tissue.
[0013] In this specification, the expression "regular pulses faster than sinus rhythm" refers to pulses that are equidistant up to a predefined variation range. For example, a sequence of pulses with an interval of 600±6 ms is included in the definition. More generally, a sequence of pulses at any given equidistant interval (e.g. slower or faster than 600 ms, e.g. 500 ms and 700 ms) up to a predefined variation range is considered hereafter as "regular pulses faster than sinus rhythm". Typically, the predefined variation range is limited to a level of 1% of the specified equidistant interval. Each reduced extrastimulus is defined with respect to the above equidistant interval. For example, if regular pacing pulses are performed with a period of 600 ms, one or more short interval pacing stimuli may be applied at 400 ms intervals following the regular rate stimulation. The terms "pulses" and "stimuli" are used interchangeably in this specification.
[0014] The above sequence simulates a premature beat (Premature Ventricle Contraction, PVC) to evoke DeEPs in arrhythmogenic tissue. In general, premature beats are relatively common. An abnormal VT circuit can be initiated and maintained only if the premature beat encounters arrhythmogenic tissue, such as tissue that exhibits slower conduction as a result of the premature beat.
[0015] In response to regular sinus rhythm pacing pulses, evoked potentials occur one at a time with a normal time delay after the stimulus. This normal delay between the pacing pulse and the resulting evoked potential is hereinafter referred to as the "first time delay." This portion of the EP mapping method is sufficient to characterize normal tissue.
[0016] In response to the extrastimulus, the evoked potentials may be delayed (relative to the first time delay) as the wave speed decreases. Regions where there is a significant relative delay (e.g., greater than 10 ms) are considered to be specific to abnormal VT circuits. If they occur, delays greater than the first time delay of these evoked potentials relative to the corresponding extrastimulus pacing pulse are hereafter referred to as "second time delays." This delay, present on the surface of the heart, can be measured on a surface ECG, for example, in the form of QRS widening.
[0017] The processor analyzes the obtained surface ECG signal to predict the presence of DeEP. In some embodiments, the processor performs the following steps: generating a regular pace (S1), then generating one or more extrastimuli potentially causing DeEP, extracting surface ECG responses to S1 and correlating these responses with each other to confirm rhythm stability, extracting the ECG response to the last S1 pace, hereafter referred to as the S1 QRS component, and extracting the ECG response to the first extrastimulus (S2 pace), hereafter referred to as the S2 QRS component, calculating the widths of the S1 and S2 QRS components, and comparing the width of the S2 QRS component to the width of the S1 QRS component to indicate the presence of DeEP.
[0018] More generally, the processor may estimate the degree of correlation by any other method known in the art, such as by using machine learning, and define a scoring to find the correlation with the highest score. For example, the scoring may be based on a pre-specified metric such as L1.
[0019] Typically, the processor is programmed with software that contains specific algorithms that enable the processor to perform each of the processor-related steps and functions outlined above.
[0020] By applying an automated DeEP prediction algorithm to assess the presence of local cardiac (e.g., ventricular) tissue sites that induce VT, the disclosed non-invasive cardiac diagnostic method may improve the safety and value of diagnostic catheterization procedures.
[0021] FIG. 1 shows a simplified diagram of a multi-channel electrocardiogram (ECG) signal measurement system 10, in accordance with one embodiment of the present invention.
[0022] For simplicity and clarity, the following description assumes a research procedure in which system 10 senses electrical signals on the body surface from heart 34 of subject 26, unless otherwise noted.
[0023] To sense electrical signals on the body surface, electrodes 30A, 30B, 30C, ... are attached to the skin of subject 26 by respective leads 31A, 31B, 31C, .... In this disclosure, electrodes 30A, 30B, 30C, ... are collectively referred to as electrodes 30, and leads 31A, 31B, 31C, ... are collectively referred to as leads 31. In a typical ECG procedure in which only electrical signals on the body surface are measured, there are ten electrodes 30 attached to the skin of subject 26 in standard positions (right arm, left arm, right leg, left leg), as well as six electrodes in the area of heart 34. In FIG. 1, four electrodes 30A, 30B, 30C, and 30D are illustrated, but are assumed to be attached to the right leg, left leg, right arm, and left arm of subject 26, respectively. For clarity, for the exemplary ECG procedure shown above, only two of the six electrodes, electrode 30E and electrode 30J, are shown in Figure 1 attached in the region of heart 34. However, in some ECG procedures there may be more or less than ten electrodes 30, and there is no limit to the number of electrodes 30 for embodiments of the present invention. It will be understood that each electrode 30 defines a respective channel of system 10.
[0024] The system 10 may be controlled by a system processor 40, which includes a processing unit 42 in communication with a memory 44. The processor 40 is typically mounted in a control console 46, which typically includes an operating control 38 having a pointing device 39, such as a mouse or trackball, by which the specialist 28 interacts with the processor. The processor operates the system 10 using software, including an ECG module 36, stored in the memory 44. Results of operations performed by the processor 40 are presented to the specialist on a display 48, which typically presents a graphic user interface to the user, a visual representation of the ECG signals sensed by the electrodes 30, and / or an image or map of the heart 34 while it is being studied. The software may be downloaded in electronic form to the processor 40, for example over a network, or alternatively or additionally, the software may be provided and / or stored on a non-transitory tangible medium, such as a magnetic, optical, or electronic memory.
[0025] An ECG module 36 is coupled to receive the electrical signals from the electrodes 30. The module is configured to analyze the signals and may present the results of the analysis on a display 48 in a standard ECG format, typically in a graphical representation that varies over time. The structure and operation of module 36 are described in more detail below with respect to Figures 2-4.
[0026] The exemplary illustration shown in Figure 1 has been chosen solely for conceptual clarity, as other types of electrophysiological sensing catheter geometries may also be used.
[0027] By utilizing surface ECG, a non-invasive measurement technique, the present system and method provide a way for physicians to know if DeEP is present in the ventricle before an invasive procedure is performed, allowing physicians to predict the need for invasive DeEP procedures. Physicians may screen many critical patients, thereby allowing better screening of patients before intracardiac procedures are utilized.
[0028] FIG. 2 illustrates an example of multiple surface ECG signals 200 indicative of a patient with intracardiac DeEP, according to an exemplary embodiment. The surface ECG signals include individual electrode signals and are collectively described herein as understood by those skilled in the art. As illustrated, an S1 pace 210 is periodically provided (shown in FIG. 2 as S1 pace signals 210.1, 210.2, 210.3 and collectively referred to as S1 pace 210) and a surface ECG signal 220 is measured. Although the present description specifies an S1 pace 210, a normal sinus rhythm may also be used. From the surface ECG signal 220, an S1 surface ECG component 230, such as the QRS envelope, is measured.
[0029] An S2 extra stimulus 240 is provided and a surface ECG signal 220 is measured. Although this description specifies an S2 extra stimulus 240, a Premature Ventricular Contraction (PVC) may also be used. From the surface ECG signal 220, an S2 surface ECG component 250, such as the QRS envelope, is measured.
[0030] For example, the envelopes of the surface ECG components 230 (for S1), 250 (for S2), such as the QRS, are evaluated for both the S1 pace 210 and the S2 extrastimulus 240. Parameters of the envelopes of the surface ECG components, such as the QRS envelope 230 (for S1), 250 (for S2), may be compared. These parameters may also include, for example, duration, voltage, area under the curve, slope, frequency analysis, and envelope height. Using the parameter comparison, the system and method predicts the presence of a physiological substrate ablation target for ventricular tachycardia (VT) by examining at least one of the parameter comparisons. Typically, the difference in the parameter comparison should be well above a few units to be clinically significant.
[0031] By way of example, a surface ECG prediction may be calculated by subtracting the width of an S1 ECG envelope, such as S1 QRS envelope 230, from the width of an S2 ECG envelope, such as S2 QRS envelope 250. By way of example, an ECG QRS widening of envelope width above a certain threshold (e.g., greater than 20 ms) indicates the presence of a DeEP target. The present system and method predict physiological substrate ablation targets for ventricular tachycardia (VT).
[0032] As will be appreciated, a check of the stability of multiple S1 responses may also be calculated. A surface ECG signal 220 is measured after each S1 pace 210 (e.g., after each S1 pace, shown as 210.1, 210.2, 210.3). From the surface ECG signal 220, an S1 surface ECG component, such as a QRS envelope 230, is measured. Parameters of the envelopes resulting from the S1 paces 210 (e.g., after each S1 pace, shown as 210.1, 210.2, 210.3) may be compared. This comparison may provide a stability of the S1 response. If the standard deviation of the comparison is below a given threshold, the timing of the response is considered clear and useful. The threshold may be set, for example, by a clinician. The threshold is a guide for determining whether the beats are similar and indicates the stability of the measurements, such as singularities for the beats. In one embodiment, a threshold of 0.85 may be used to identify a stable configuration. As will be appreciated, 0.85 is exemplary and other stability measurements, such as 0.85, 0.75, 0.9, or above, may indicate a stable configuration for the measurement. The threshold may also be modified by the clinician to meet the desired stability during a given measurement. An average of the S1 responses, such as an average of three S1 responses, or the most recent S1 response, may be used in subsequent calculations of QRS widening or other parameters.
[0033] Figure 3 provides examples of multiple surface ECG signals having QRS widening associated with cases indicative of the presence of DeEP, collectively shown as Figures 3A, 3B, and 3C, according to an exemplary embodiment. As in Figure 2, the signals are measured by a surface ECG 220 using S1 pacing 210 and S2 extrastimulation 240. Again, the surface ECG signals include individual electrode signals, collectively described herein as understood by those skilled in the art. Figure 3C shows the relationship between surface QRS widening (y-axis) and three DeEP classifications.
[0034] Referring to Figure 3A, a body surface signal 300 is shown for both an S1 310 pacing configuration and an S2 340 pacing configuration. Using the surface width of the QRS envelope as the parameter of interest, the surface width after the S1 pacing signal 310 is shown as 152 ms and the surface width after the S2 extra stimulus 340 is shown as 150 ms. In this scenario shown in Figure 3A, the difference is effectively 0 ms, indicating no ablation target is present.
[0035] Referring to Figure 3B, the body surface signal 360 for both the S1 310 and S2 340 pacing configurations is shown. Using the surface width of the QRS envelope as the parameter of interest as in Figure 3A, the surface width after the S1 pacing signal 310 is shown as 168 ms and the surface width after the S2 extra stimulus 340 is shown as 195 ms. In this scenario shown in Figure 3B, the difference is effectively 30 ms, indicating the presence of a significant DeEP.
[0036] Referring to FIG. 3C, a plot 375 of the relationship between surface QRS widening (y-axis) and three DeEP classification categories is shown. A first category of “No ablation targets” 380 is shown having a DeEP between 0-10 ms. A second category of “DeEP positive” 390 is shown having a DeEP between 10 ms and 50 ms. A third category of “Prominent DeEP” 395 is shown having a DeEP above 50 ms.
[0037] FIG. 4 illustrates the basic steps of a method 400 for non-invasively detecting abnormal electrical propagation in the heart, according to one embodiment.
[0038] The method 400 includes receiving a pacing signal for application to a patient's heart at step 410. The pacing signal includes (i) a series of regular pacing stimuli slightly faster than sinus rhythm and (ii) one or more abnormal pacing stimuli at abnormal intervals that are shorter than the intervals between the regular rates.
[0039] At step 420, the method 400 includes evaluating the envelope of the surface ECG components after the regular pacing stimulation, such as the QRS envelope duration, the surface ECG component duration, the voltage, the area under the curve, the slope, the frequency resolution, and / or the envelope height.
[0040] In step 430, the method 400 includes evaluating the stability of the surface ECG components obtained during the regular pacing stimulation.
[0041] At step 440, method 400 includes evaluating the envelope of the surface ECG component following the abnormal pacing stimulus. In one embodiment, the evaluated component is the same as the component evaluated at step 420. The evaluated components may be, for example, the QRS envelope duration, the surface ECG component duration, the voltage, the area under the curve, the slope, the frequency resolution, and / or the envelope height.
[0042] At step 450, the method 400 includes comparing the assessed component after the abnormal pacing stimulus to the assessed component after the regular pacing stimulus, for example the difference in the width of the QRS signal of the two signals.
[0043] In step 460, the method 400 includes outputting the comparison as an indication of the presence of DeEP in the patient's heart.
[0044] The present system and method provide for detection of patients with substrate ablation targets based on 12-lead ECG prior to the ablation procedure. Furthermore, the prediction rule can predict that ambulatory patients without VT episodes may be susceptible to developing VT based on association with arrhythmogenic potentials. This concept should be validated in a larger dataset and is ideal for training and testing using surface ECG envelope with artificial intelligence algorithms.
[0045] The exemplary flow chart shown in Figure 4 has been chosen purely for the purposes of conceptual clarity. This embodiment may also include additional steps of an algorithm. This step, and other possible steps, have been intentionally omitted from the disclosure herein in order to provide a more simplified flow chart.
[0046] Pacing may occur from different locations and / or the location of the pacing signal may be varied. Figures 5 and 6 show the results of a 12-lead BS ECG configuration when pacing is performed from different locations. By way of example, for a given patient, multiple locations of the pacing signal may be used in recording the signal (measurement). For example, in Figure 5, pacing is provided from the coronary sinus, resulting in a recorded surface ECG signal, and in Figure 6, pacing is provided from the right ventricular apex, resulting in a recorded surface ECG signal. In each of Figures 5 and 6, the characteristics of the QRS envelope, or the degree to which the QRS envelope changes, may be different even for the same patient.
[0047] FIG. 5 shows an example of multiple surface ECG signals 500 of a patient when pacing is performed from the coronary sinus. In FIG. 5, the characteristics of the QRS envelope are shown, repeated over two beats. Again, the surface ECG signals include individual electrode signals, collectively described herein as will be understood by those skilled in the art. The QRS envelope includes S1 and S2, as described above. For example, the envelope of the surface ECG components for S1 and S2, such as the QRS, is evaluated for both the S1 pace and the S2 extrastimulus, as described. The parameters of the envelope of the surface ECG components, such as the QRS envelope S1, S2, may be compared. Surface signals 500 are shown for both the S1 310 and S2 340 pacing configurations. As described above, the surface width of the QRS envelope may be used as a parameter of interest to measure the surface width after the S1 pace signal 310 and the surface width after the S2 extrastimulus 340. In this scenario, the differences may be compared as described to determine whether an ablation target is present.
[0048] FIG. 6 illustrates an example of multiple surface ECG signals 600 of the patient of FIG. 5 when pacing is performed from the right ventricular apex. Again, the surface ECG signals include individual electrode signals and are collectively described herein as understood by those skilled in the art. In FIG. 6, the characteristics of the QRS envelope are shown, which repeat over two beats. This QRS envelope includes S1 and S2 as described above. For example, the envelope of the surface ECG components for S1 and S2, such as the QRS, is evaluated for both the S1 pace and the S2 extrastimulus, as described. The parameters of the envelope of the surface ECG components, such as the QRS envelope S1, S2, may be compared. The surface signals 600 relate to both the S1 and S2 pacing configurations. As described above, the surface width of the QRS envelope may be used as a parameter of interest to measure the surface width after the S1 pacing signal and the surface width after the S2 extrastimulus. In this scenario, the differences may be compared as described to determine whether an ablation target is present.
[0049] 7 illustrates a method 700 for automatically assessing a surface ECG for the presence of DeEP using pacing from different locations. Similar to the method described above with respect to FIG. 4, method 700 includes receiving pacing signals to be applied to the patient's heart at different locations, step 710. The pacing signals include (i) a series of regular pacing stimuli slightly faster than sinus rhythm, and (ii) one or more abnormal pacing stimuli at abnormal intervals that are shorter than the intervals of the regular rate. The pacing signals may be provided at different locations around the patient's heart.
[0050] At step 720, the method 700 includes evaluating the envelope of the surface ECG components after the regular pacing stimulation, such as the QRS envelope duration, the surface ECG component duration, the voltage, the area under the curve, the slope, the frequency resolution, and / or the envelope height.
[0051] At step 730, the method 700 includes evaluating the stability of the surface ECG components obtained during the regular pacing stimulation.
[0052] At step 740, method 700 includes evaluating the envelope of the surface ECG component following the abnormal pacing stimulus. In one embodiment, the evaluated component is the same as the component evaluated at step 720. The evaluated components may be, for example, the QRS envelope duration, the surface ECG component duration, the voltage, the area under the curve, the slope, the frequency resolution, and / or the envelope height.
[0053] At step 750, the method 700 includes comparing the assessed component after the abnormal pacing stimulus to the assessed component after the regular pacing stimulus, for example the difference in the width of the QRS signal of the two signals.
[0054] Method 700 may be repeated for additional pacing locations to further measure the difference in QRS signal width of the two signals in the presence of different pacing signals.
[0055] At step 760, the method 700 includes outputting the comparison based on the measured QRS signals for the different pacing locations as an indication for the presence of DeEP in the patient's heart.
[0056] The present system and method provide for detection of patients with substrate ablation targets based on 12-lead ECG prior to the ablation procedure. Furthermore, the prediction rule can predict that ambulatory patients without VT episodes may be susceptible to developing VT based on association with arrhythmogenic potentials. This concept should be validated in a larger dataset and is ideal for training and testing using surface ECG envelope with artificial intelligence algorithms.
[0057] The exemplary flow chart shown in Figure 7 has been chosen purely for the purposes of conceptual clarity. This embodiment may also include additional steps of an algorithm. This step, and other possible steps, have been intentionally omitted from the disclosure herein in order to provide a more simplified flow chart.
[0058] Although the embodiments described herein primarily address cardiac diagnostic applications, the methods and systems described herein may also be used in other medical applications.
[0059] It will be understood that the above embodiments have been cited by way of example, and that the present invention is not limited to what has been particularly shown and described above. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described in the above specification, as well as variations and modifications thereof not disclosed in the prior art that will occur to those skilled in the art upon reading the foregoing description.
[0060] [Embodiment] (1) A method for non-invasively detecting abnormal electrical propagation in a heart, the method comprising: receiving a pacing signal for application to the patient's heart, the pacing signal including (i) a series of regular pacing stimuli slightly faster than sinus rhythm, and (ii) one or more extrastimuli at abnormal intervals shorter than the intervals between the regular rates; evaluating an envelope of a surface ECG component after said regular pacing stimulus; assessing the stability of the surface ECG components acquired during the regular pacing stimulation; evaluating the envelope of the post-extrastimulus surface ECG component; and comparing the assessed component after the extra-stimulus to the assessed component after the regular pacing stimulus; and outputting the comparison as an indication of the presence of decrement-evoked potentials (DeEP) in the patient's heart. (2) The method of embodiment 1, wherein the evaluated component is the duration of the QRS envelope. (3) The method of embodiment 1, wherein the evaluated component is the duration of a surface ECG component. (4) The method of claim 1, wherein the evaluated component is voltage. (5) The method of claim 1, wherein the evaluated component is the area under the curve.
[0061] (6) The method of claim 1, wherein the evaluated component is a gradient. (7) The method of claim 1, wherein the evaluated component is a frequency analysis. (8) The method of claim 1, wherein the evaluated component is the height of the envelope. (9) The method of embodiment 1, wherein the ECG component for DeEP between 0 and 10 milliseconds indicates no ablation target. (10) The method of embodiment 1, wherein the ECG component for DeEP between 10 and 50 milliseconds indicates DeEP positive.
[0062] (11) The method of embodiment 1, wherein the ECG component for DeEP exceeding 50 milliseconds indicates the presence of significant DeEP. (12) The method of embodiment 1, wherein the series of regular pacing stimuli at sinus rhythm intervals comprises a normal sinus rhythm of the heart. (13) The method of embodiment 12, wherein the one or more abnormal pacing stimuli include a premature ventricular contraction. (14) A system for assessment of electrical propagation in a heart, the system comprising: An interface, a pacing signal applied to the patient's heart, the pacing signal including (i) a series of regular pacing stimuli slightly faster than a sinus rhythm interval, and (ii) one or more extrastimuli at abnormal intervals shorter than the regular rate interval; an interface configured to receive a cardiac signal sensed by a surface ECG in response to the pacing signal; 1. A processor comprising: assessing an envelope of a surface ECG component after said regular pacing stimulus; assessing the stability of the surface ECG components obtained during the regular pacing stimulation; evaluating the envelope of the post-extrastimulus surface ECG component; a processor configured to compare the assessed component after the extra-stimulus with the assessed component after the regular pacing stimulus; The system, wherein the interface is further configured to output the comparison as an indication of a presence of a decreased evoked potential (DeEP) in the patient's heart. (15) The system of embodiment 14, wherein the evaluated component is the duration of the QRS envelope.
[0063] (16) The system of embodiment 14, wherein the evaluated component is the duration of a surface ECG component. (17) The system of claim 14, wherein the evaluated component is voltage. (18) The system of embodiment 14, wherein the evaluated component is an area under the curve. (19) The system of embodiment 14, wherein the evaluated component is a slope. (20) The system of embodiment 14, wherein the evaluated component is frequency analysis.
[0064] (21) The system of claim 14, wherein the evaluated component is the height of the envelope. (22) The system described in embodiment 14, wherein the ECG component for DeEP between 0 and 10 milliseconds indicates no ablation target. (23) The system of embodiment 14, wherein the ECG component for DeEP between 10 and 50 milliseconds indicates DeEP positivity. (24) The system of embodiment 14, wherein the ECG components for DeEP exceeding 50 milliseconds indicate the presence of significant DeEP. (25) The system described in embodiment 14, wherein the series of regular pacing stimuli at sinus rhythm intervals comprises a normal sinus rhythm of the heart.
[0065] (26) The system described in embodiment 25, wherein the one or more abnormal pacing stimuli include a premature ventricular contraction.
Claims
1. 1. A system for assessment of electrical propagation in a heart, the system comprising: An interface, a pacing signal applied to the patient's heart, the pacing signal including (i) a series of regular pacing stimuli slightly faster than sinus rhythm intervals, and (ii) one or more extrastimuli at abnormal intervals shorter than the regular rate intervals; an interface configured to receive a cardiac signal sensed by a surface ECG in response to the pacing signal; 1. A processor comprising: assessing an envelope of a surface ECG component after said regular pacing stimulus; assessing the stability of the surface ECG components obtained during the regular pacing stimulation; evaluating the envelope of the post-extrastimulus surface ECG component; a processor configured to compare the assessed component after the extra-stimulus with the assessed component after the regular pacing stimulus; The system, wherein the interface is further configured to output the comparison as an indication of a presence of a decreased evoked potential (DeEP) in the patient's heart.
2. The system of claim 1 , wherein the evaluated component is the duration of the QRS envelope.
3. The system of claim 1 , wherein the evaluated component is a duration of a surface ECG component.
4. The system of claim 1 , wherein the evaluated component is a voltage.
5. The system of claim 1 , wherein the evaluated component is an area under the curve.
6. The system of claim 1 , wherein the evaluated component is a slope.
7. The system of claim 1 , wherein the evaluated component is a frequency analysis.
8. The system of claim 1 , wherein the evaluated component is a height of the envelope.
9. The system of claim 1 , wherein the ECG component for DeEP between 0 and 10 milliseconds indicates no ablation target.
10. The system of claim 1 , wherein the ECG component for DeEP between 10 and 50 milliseconds indicates a DeEP positivity.
11. The system of claim 1 , wherein the ECG component for a DeEP greater than 50 milliseconds indicates the presence of significant DeEP.
12. The system of claim 1 , wherein the series of regular pacing stimuli at sinus rhythm intervals comprises a normal sinus rhythm of the heart.
13. The system of claim 12 , wherein the one or more abnormal pacing stimuli comprises a premature ventricular contraction.
14. 1. A method for non-invasively detecting abnormal electrical propagation in a heart, the method comprising: receiving a pacing signal for application to the patient's heart, the pacing signal including (i) a series of regular pacing stimuli slightly faster than sinus rhythm, and (ii) one or more extrastimuli at abnormal intervals shorter than the intervals between the regular rates; evaluating an envelope of a surface ECG component after said regular pacing stimulus; assessing the stability of the surface ECG components acquired during the regular pacing stimulation; evaluating the envelope of the post-extrastimulus surface ECG component; and comparing the assessed component after the extra-stimulus to the assessed component after the regular pacing stimulus; and outputting the comparison as an indication of a presence of decreased evoked potentials (DeEPs) in the patient's heart.
15. The method of claim 14 , wherein the evaluated component is the duration of the QRS envelope.
16. The method of claim 14 , wherein the evaluated component is the duration of a surface ECG component.
17. The method of claim 14 , wherein the evaluated component is a voltage.
18. The method of claim 14 , wherein the evaluated component is the area under the curve.
19. The method of claim 14 , wherein the evaluated component is a gradient.
20. The method of claim 14 , wherein the evaluated component is a frequency analysis.
21. The method of claim 14 , wherein the evaluated component is the height of the envelope.
22. The method of claim 14, wherein the ECG component for DeEP between 0 and 10 milliseconds indicates no ablation target.
23. The method of claim 14, wherein the ECG component for DeEP between 10-50 milliseconds indicates a DeEP positivity.
24. The method of claim 14, wherein the ECG component for a DeEP greater than 50 milliseconds indicates the presence of significant DeEP.
25. 15. The method of claim 14, wherein the series of regular pacing stimuli at sinus rhythm intervals comprises a normal sinus rhythm of the heart.
26. 26. The method of claim 25, wherein the one or more abnormal pacing stimuli comprises a premature ventricular contraction.
